Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 194

1.

Towards multiplexed near-infrared cellular imaging using gold nanostar arrays with tunable fluorescence enhancement.

Theodorou IG, Ruenraroengsak P, Gonzalez-Carter DA, Jiang Q, Yagüe E, Aboagye EO, Coombes RC, Porter AE, Ryan MP, Xie F.

Nanoscale. 2019 Jan 16. doi: 10.1039/c8nr09409h. [Epub ahead of print]

PMID:
30648720
2.

3D growth of cancer cells elicits sensitivity to kinase inhibitors but not lipid metabolism modifiers.

Jones DT, Valli A, Haider S, Zang Q, Smethurst E, Schug ZT, Peck B, Aboagye EO, Critchlow SE, Schulze A, Gottlieb E, Wakelam MJO, Harris AL.

Mol Cancer Ther. 2018 Nov 26. pii: molcanther.0857.2018. doi: 10.1158/1535-7163.MCT-17-0857. [Epub ahead of print]

PMID:
30478149
3.

The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death.

Kaliszczak M, van Hechanova E, Li Y, Alsadah H, Parzych K, Auner HW, Aboagye EO.

Br J Cancer. 2018 Nov;119(10):1278-1287. doi: 10.1038/s41416-018-0232-5. Epub 2018 Oct 15.

PMID:
30318510
4.

Clinical translation of [18F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer.

Dubash SR, Merchant S, Heinzmann K, Mauri F, Lavdas I, Inglese M, Kozlowski K, Rama N, Masrour N, Steel JF, Thornton A, Lim AK, Lewanski C, Cleator S, Coombes RC, Kenny L, Aboagye EO.

Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2285-2299. doi: 10.1007/s00259-018-4098-9. Epub 2018 Sep 27.

5.

Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications.

Fu R, Carroll L, Yahioglu G, Aboagye EO, Miller PW.

ChemMedChem. 2018 Dec 6;13(23):2466-2478. doi: 10.1002/cmdc.201800624. Epub 2018 Nov 15. Review.

PMID:
30246488
6.

Discovery of pre-therapy 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients.

Arshad MA, Thornton A, Lu H, Tam H, Wallitt K, Rodgers N, Scarsbrook A, McDermott G, Cook GJ, Landau D, Chua S, O'Connor R, Dickson J, Power DA, Barwick TD, Rockall A, Aboagye EO.

Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):455-466. doi: 10.1007/s00259-018-4139-4. Epub 2018 Sep 1.

7.

Fluorescence enhancement from single gold nanostars: towards ultra-bright emission in the first and second near-infrared biological windows.

Theodorou IG, Jiang Q, Malms L, Xie X, Coombes RC, Aboagye EO, Porter AE, Ryan MP, Xie F.

Nanoscale. 2018 Aug 23;10(33):15854-15864. doi: 10.1039/c8nr04567d.

PMID:
30105338
8.

Synthesis, Radiolabelling and In Vitro Imaging of Multifunctional Nanoceramics.

Lledos M, Mirabello V, Sarpaki S, Ge H, Smugowski HJ, Carroll L, Aboagye EO, Aigbirhio FI, Botchway SW, Dilworth JR, Calatayud DG, Plucinski PK, Price GJ, Pascu SI.

ChemNanoMat. 2018 Apr;4(4):361-372. doi: 10.1002/cnma.201700378. Epub 2018 Feb 8.

9.

Histogram analysis of apparent diffusion coefficient from whole-body diffusion-weighted MRI to predict early response to chemotherapy in patients with metastatic colorectal cancer: preliminary results.

Lavdas I, Rockall AG, Daulton E, Kozlowski K, Honeyfield L, Aboagye EO, Sharma R.

Clin Radiol. 2018 Sep;73(9):832.e9-832.e16. doi: 10.1016/j.crad.2018.04.011. Epub 2018 May 21.

PMID:
29793720
10.

Selective Inhibition of Histone Deacetylation in Melanoma Increases Targeted Gene Delivery by a Bacteriophage Viral Vector.

Campbell S, Suwan K, Waramit S, Aboagye EO, Hajitou A.

Cancers (Basel). 2018 Apr 21;10(4). pii: E125. doi: 10.3390/cancers10040125.

11.

ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.

Patel H, Periyasamy M, Sava GP, Bondke A, Slafer BW, Kroll SHB, Barbazanges M, Starkey R, Ottaviani S, Harrod A, Aboagye EO, Buluwela L, Fuchter MJ, Barrett AGM, Coombes RC, Ali S.

Mol Cancer Ther. 2018 Jun;17(6):1156-1166. doi: 10.1158/1535-7163.MCT-16-0847. Epub 2018 Mar 15.

12.

Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'-18F-Fluorothymidine Uptake After Therapy in a Colorectal Cancer Model.

Schelhaas S, Wachsmuth L, Hermann S, Rieder N, Heller A, Heinzmann K, Honess DJ, Smith DM, Fricke IB, Just N, Doblas S, Sinkus R, Döring C, Schäfers KP, Griffiths JR, Faber C, Schneider R, Aboagye EO, Jacobs AH.

J Nucl Med. 2018 Jul;59(7):1063-1069. doi: 10.2967/jnumed.117.206250. Epub 2018 Feb 23.

13.

Repeatability of quantitative 18F-FLT uptake measurements in solid tumors: an individual patient data multi-center meta-analysis.

Kramer GM, Liu Y, de Langen AJ, Jansma EP, Trigonis I, Asselin MC, Jackson A, Kenny L, Aboagye EO, Hoekstra OS, Boellaard R; QuIC-ConCePT consortium.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):951-961. doi: 10.1007/s00259-017-3923-x. Epub 2018 Jan 23.

14.

Towards an MMP-2-activated molecular agent for cancer imaging.

Cowell S, Carroll L, Lavdas I, Aboagye EO, Vilar R.

Dalton Trans. 2018 Jan 30;47(5):1530-1534. doi: 10.1039/c7dt03108d.

15.

Correction to: The relationship between endogenous thymidine concentrations and [18F]FLT uptake in a range of preclinical tumour models.

Heinzmann K, Honess DJ, Lewis DY, Smith DM, Cawthorne C, Keen H, Heskamp S, Schelhaas S, Witney TH, Soloviev D, Williams KJ, Jacobs AH, Aboagye EO, Griffiths JR, Brindle KM.

EJNMMI Res. 2017 Dec 15;7(1):99. doi: 10.1186/s13550-017-0349-1.

16.

3'-Deoxy-3'-[18F]Fluorothymidine Uptake Is Related to Thymidine Phosphorylase Expression in Various Experimental Tumor Models.

Schelhaas S, Heinzmann K, Honess DJ, Smith DM, Keen H, Heskamp S, Witney TH, Besret L, Doblas S, Griffiths JR, Aboagye EO, Jacobs AH.

Mol Imaging Biol. 2018 Apr;20(2):194-199. doi: 10.1007/s11307-017-1125-3.

17.

Erratum to: Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer.

Saleem A, Searle GE, Kenny LM, Huiban M, Kozlowski K, Waldman AD, Woodley L, Palmieri C, Lowdell C, Kaneko T, Murphy PS, Lau MR, Aboagye EO, Coombes RC.

EJNMMI Res. 2017 Sep 8;7(1):74. doi: 10.1186/s13550-017-0323-y. No abstract available.

18.

Fully automatic, multiorgan segmentation in normal whole body magnetic resonance imaging (MRI), using classification forests (CFs), convolutional neural networks (CNNs), and a multi-atlas (MA) approach.

Lavdas I, Glocker B, Kamnitsas K, Rueckert D, Mair H, Sandhu A, Taylor SA, Aboagye EO, Rockall AG.

Med Phys. 2017 Oct;44(10):5210-5220. doi: 10.1002/mp.12492. Epub 2017 Aug 31.

19.

Highlights lecture EANM 2016: "Embracing molecular imaging and multi-modal imaging: a smart move for nuclear medicine towards personalized medicine".

Aboagye EO, Kraeber-Bodéré F.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1559-1574. doi: 10.1007/s00259-017-3704-6. Epub 2017 Jun 8. Review.

20.

Molecular mechanisms of hypoxia in cancer.

Challapalli A, Carroll L, Aboagye EO.

Clin Transl Imaging. 2017;5(3):225-253. doi: 10.1007/s40336-017-0231-1. Epub 2017 May 11. Review.

21.

Baseline and longitudinal variability of normal tissue uptake values of [18F]-fluorothymidine-PET images.

Cysouw MCF, Kramer GM, Frings V, De Langen AJ, Wondergem MJ, Kenny LM, Aboagye EO, Kobe C, Wolf J, Hoekstra OS, Boellaard R.

Nucl Med Biol. 2017 Aug;51:18-24. doi: 10.1016/j.nucmedbio.2017.05.002. Epub 2017 May 10.

22.

Reverse Classification Accuracy: Predicting Segmentation Performance in the Absence of Ground Truth.

Valindria VV, Lavdas I, Bai W, Kamnitsas K, Aboagye EO, Rockall AG, Rueckert D, Glocker B.

IEEE Trans Med Imaging. 2017 Aug;36(8):1597-1606. doi: 10.1109/TMI.2017.2665165. Epub 2017 Apr 17.

23.

Preclinical Applications of 3'-Deoxy-3'-[18F]Fluorothymidine in Oncology - A Systematic Review.

Schelhaas S, Heinzmann K, Bollineni VR, Kramer GM, Liu Y, Waterton JC, Aboagye EO, Shields AF, Soloviev D, Jacobs AH.

Theranostics. 2017 Jan 1;7(1):40-50. doi: 10.7150/thno.16676. eCollection 2017. Review.

24.

Evaluation of 18F-fluorothymidine positron emission tomography ([18F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer.

Sharma R, Mapelli P, Hanna GB, Goldin R, Power D, Al-Nahhas A, Merchant S, Ramaswami R, Challapalli A, Barwick T, Aboagye EO.

EJNMMI Res. 2016 Dec;6(1):81. Epub 2016 Nov 16.

25.

Imaging biomarker roadmap for cancer studies.

O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, deSouza NM, Dickson JC, Dive C, Evelhoch JL, Faivre-Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V, Griffiths JR, Groves AM, Halligan S, Harris AL, Hawkes DJ, Hoekstra OS, Huang EP, Hutton BF, Jackson EF, Jayson GC, Jones A, Koh DM, Lacombe D, Lambin P, Lassau N, Leach MO, Lee TY, Leen EL, Lewis JS, Liu Y, Lythgoe MF, Manoharan P, Maxwell RJ, Miles KA, Morgan B, Morris S, Ng T, Padhani AR, Parker GJ, Partridge M, Pathak AP, Peet AC, Punwani S, Reynolds AR, Robinson SP, Shankar LK, Sharma RA, Soloviev D, Stroobants S, Sullivan DC, Taylor SA, Tofts PS, Tozer GM, van Herk M, Walker-Samuel S, Wason J, Williams KJ, Workman P, Yankeelov TE, Brindle KM, McShane LM, Jackson A, Waterton JC.

Nat Rev Clin Oncol. 2017 Mar;14(3):169-186. doi: 10.1038/nrclinonc.2016.162. Epub 2016 Oct 11. Review.

26.

Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography.

Slade RL, Pisaneschi F, Nguyen QD, Smith G, Carroll L, Beckley A, Kaliszczak MA, Aboagye EO.

PLoS One. 2016 Aug 23;11(8):e0161427. doi: 10.1371/journal.pone.0161427. eCollection 2016.

27.

The relationship between endogenous thymidine concentrations and [(18)F]FLT uptake in a range of preclinical tumour models.

Heinzmann K, Honess DJ, Lewis DY, Smith DM, Cawthorne C, Keen H, Heskamp S, Schelhaas S, Witney TH, Soloviev D, Williams KJ, Jacobs AH, Aboagye EO, Griffiths JR, Brindle KM.

EJNMMI Res. 2016 Dec;6(1):63. doi: 10.1186/s13550-016-0218-3. Epub 2016 Aug 11. Erratum in: EJNMMI Res. 2017 Dec 15;7(1):99.

28.

AKT activation controls cell survival in response to HDAC6 inhibition.

Kaliszczak M, Trousil S, Ali T, Aboagye EO.

Cell Death Dis. 2016 Jun 30;7(6):e2286. doi: 10.1038/cddis.2016.180.

29.

Significant metal enhanced fluorescence of Ag2S quantum dots in the second near-infrared window.

Theodorou IG, Jawad ZA, Qin H, Aboagye EO, Porter AE, Ryan MP, Xie F.

Nanoscale. 2016 Jul 14;8(26):12869-73. doi: 10.1039/c6nr03220f. Epub 2016 Jun 17.

30.

The novel choline kinase inhibitor ICL-CCIC-0019 reprograms cellular metabolism and inhibits cancer cell growth.

Trousil S, Kaliszczak M, Schug Z, Nguyen QD, Tomasi G, Favicchio R, Brickute D, Fortt R, Twyman FJ, Carroll L, Kalusa A, Navaratnam N, Adejumo T, Carling D, Gottlieb E, Aboagye EO.

Oncotarget. 2016 Jun 14;7(24):37103-37120. doi: 10.18632/oncotarget.9466.

31.

Clinical Translation of a Click-Labeled 18F-Octreotate Radioligand for Imaging Neuroendocrine Tumors.

Dubash SR, Keat N, Mapelli P, Twyman F, Carroll L, Kozlowski K, Al-Nahhas A, Saleem A, Huiban M, Janisch R, Frilling A, Sharma R, Aboagye EO.

J Nucl Med. 2016 Aug;57(8):1207-13. doi: 10.2967/jnumed.115.169532. Epub 2016 May 12.

32.

Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments.

Peck B, Schug ZT, Zhang Q, Dankworth B, Jones DT, Smethurst E, Patel R, Mason S, Jiang M, Saunders R, Howell M, Mitter R, Spencer-Dene B, Stamp G, McGarry L, James D, Shanks E, Aboagye EO, Critchlow SE, Leung HY, Harris AL, Wakelam MJO, Gottlieb E, Schulze A.

Cancer Metab. 2016 Apr 1;4:6. doi: 10.1186/s40170-016-0146-8. eCollection 2016.

33.

Functional imaging of hepatocellular carcinoma.

Hoogenboom TC, Thursz M, Aboagye EO, Sharma R.

Hepat Oncol. 2016 Apr;3(2):137-153. doi: 10.2217/hep-2015-0005. Epub 2016 Mar 29. Review.

34.

Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring.

Challapalli A, Aboagye EO.

Front Oncol. 2016 Feb 29;6:44. doi: 10.3389/fonc.2016.00044. eCollection 2016. Review.

35.

Correction: Microwave gallium-68 radiochemistry for kinetically stable bis(thiosemicarbazone) complexes: structural investigations and cellular uptake under hypoxia.

Alam IS, Arrowsmith RL, Cortezon-Tamarit F, Twyman F, Kociok-Köhn G, Botchway SW, Dilworth JR, Carroll L, Aboagye EO, Pascu SI.

Dalton Trans. 2016 Feb 28;45(8):3650. doi: 10.1039/c6dt90021f. No abstract available.

36.

The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer.

Hopkins TG, Mura M, Al-Ashtal HA, Lahr RM, Abd-Latip N, Sweeney K, Lu H, Weir J, El-Bahrawy M, Steel JH, Ghaem-Maghami S, Aboagye EO, Berman AJ, Blagden SP.

Nucleic Acids Res. 2016 Feb 18;44(3):1227-46. doi: 10.1093/nar/gkv1515. Epub 2015 Dec 29.

37.

Microwave gallium-68 radiochemistry for kinetically stable bis(thiosemicarbazone) complexes: structural investigations and cellular uptake under hypoxia.

Alam IS, Arrowsmith RL, Cortezon-Tamarit F, Twyman F, Kociok-Köhn G, Botchway SW, Dilworth JR, Carroll L, Aboagye EO, Pascu SI.

Dalton Trans. 2016 Jan 7;45(1):144-55. doi: 10.1039/c5dt02537k. Erratum in: Dalton Trans. 2016 Feb 28;45(8):3650.

38.

PET Imaging of Steroid Hormone Receptor Expression.

Allott L, Smith G, Aboagye EO, Carroll L.

Mol Imaging. 2015;14(10):534-50. doi: 10.2310/7290.2015.00026. Review.

39.

Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid Tumors.

Sharma R, Kallur KG, Ryu JS, Parameswaran RV, Lindman H, Avril N, Gleeson FV, Lee JD, Lee KH, O'Doherty MJ, Groves AM, Miller MP, Somer EJ, Coombes CR, Aboagye EO.

J Nucl Med. 2015 Dec;56(12):1855-61. doi: 10.2967/jnumed.115.158253. Epub 2015 Sep 17.

40.

Apparent Diffusion Coefficient of Normal Abdominal Organs and Bone Marrow From Whole-Body DWI at 1.5 T: The Effect of Sex and Age.

Lavdas I, Rockall AG, Castelli F, Sandhu RS, Papadaki A, Honeyfield L, Waldman AD, Aboagye EO.

AJR Am J Roentgenol. 2015 Aug;205(2):242-50. doi: 10.2214/AJR.14.13964.

PMID:
26204271
41.

Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [(18)F]fluciclatide kinetics and [ (15)O]H 2O PET.

Kenny LM, Tomasi G, Turkheimer F, Larkin J, Gore M, Brock CS, Mangar S, Aboagye EO.

EJNMMI Res. 2014 Dec;4(1):30. doi: 10.1186/s13550-014-0030-x. Epub 2014 Aug 8.

42.

Exploiting altered patterns of choline kinase-alpha expression on human prostate tissue to prognosticate prostate cancer.

Challapalli A, Trousil S, Hazell S, Kozlowski K, Gudi M, Aboagye EO, Mangar S.

J Clin Pathol. 2015 Sep;68(9):703-9. doi: 10.1136/jclinpath-2015-202859. Epub 2015 Jun 3.

PMID:
26041862
43.

Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer.

Saleem A, Searle GE, Kenny LM, Huiban M, Kozlowski K, Waldman AD, Woodley L, Palmieri C, Lowdell C, Kaneko T, Murphy PS, Lau MR, Aboagye EO, Coombes RC.

EJNMMI Res. 2015 Apr 30;5:30. doi: 10.1186/s13550-015-0103-5. eCollection 2015. Erratum in: EJNMMI Res. 2017 Sep 18;7(1):76. EJNMMI Res. 2017 Sep 8;7(1):74.

44.

Metabolically active tumour volume segmentation from dynamic [(18)F]FLT PET studies in non-small cell lung cancer.

Hoyng LL, Frings V, Hoekstra OS, Kenny LM, Aboagye EO, Boellaard R.

EJNMMI Res. 2015 Apr 23;5:26. doi: 10.1186/s13550-015-0102-6. eCollection 2015.

45.

Design, synthesis and initial characterisation of a radiolabelled [(18)F]pyrimidoindolone probe for detecting activated caspase-3/7.

Udemba A, Smith G, Nguyen QD, Kaliszczak M, Carroll L, Fortt R, Fuchter MJ, Aboagye EO.

Org Biomol Chem. 2015 May 21;13(19):5418-23. doi: 10.1039/c5ob00058k.

PMID:
25865735
46.

Mn-salen catalysed benzylic C-H activation for the synthesis of aryl [(18)F]CF3-containing PET probes.

Carroll L, Evans HL, Spivey AC, Aboagye EO.

Chem Commun (Camb). 2015 May 18;51(40):8439-41. doi: 10.1039/c4cc05762g.

47.

3'-Deoxy-3'-¹⁸F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer.

Challapalli A, Barwick T, Pearson RA, Merchant S, Mauri F, Howell EC, Sumpter K, Maxwell RJ, Aboagye EO, Sharma R.

Eur J Nucl Med Mol Imaging. 2015 May;42(6):831-40. doi: 10.1007/s00259-015-3000-2. Epub 2015 Feb 12.

PMID:
25673055
48.

Radiopharmaceuticals as probes to characterize tumour tissue.

Alam IS, Arshad MA, Nguyen QD, Aboagye EO.

Eur J Nucl Med Mol Imaging. 2015 Apr;42(4):537-61. doi: 10.1007/s00259-014-2984-3. Epub 2015 Feb 3. Review.

PMID:
25647074
49.

Luciferase fragment complementation imaging in preclinical cancer studies.

Lake MC, Aboagye EO.

Oncoscience. 2014 Jun 1;1(5):310-25. eCollection 2014. Review.

50.

Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress.

Schug ZT, Peck B, Jones DT, Zhang Q, Grosskurth S, Alam IS, Goodwin LM, Smethurst E, Mason S, Blyth K, McGarry L, James D, Shanks E, Kalna G, Saunders RE, Jiang M, Howell M, Lassailly F, Thin MZ, Spencer-Dene B, Stamp G, van den Broek NJ, Mackay G, Bulusu V, Kamphorst JJ, Tardito S, Strachan D, Harris AL, Aboagye EO, Critchlow SE, Wakelam MJ, Schulze A, Gottlieb E.

Cancer Cell. 2015 Jan 12;27(1):57-71. doi: 10.1016/j.ccell.2014.12.002.

Supplemental Content

Loading ...
Support Center